Who Needs The BBB? Aduhelm Shows Medicare Price ‘Negotiation’ Is Already Here
Biogen is making clear that its decision to cut the price of the Alzheimer’s therapy Aduhelm is in no way tied to the upcoming US Medicare coverage decision for the treatment. But it still shows how Medicare can already ‘negotiate’ prices even without explicit statutory authority.
You may also be interested in...
Members of Congress in favor of giving FTC authority to impose monetary relief orders against firms linked to false advertising likely were caught off guard when West Virginia Democrat said he wouldn’t vote for legislation with $2.2 trillion for climate change, tax and social programs that President Biden made a primary plank of his Capitol Hill strategy and that the House passed in November.
With CMS draft decision expected next month on amyloid-clearing antibodies for Alzheimer’s, Biogen slashes Aduhem’s price 50% to $28,200 per year. Move reverses another aspect of the approval that drew criticism, including the expansive label and long horizon for confirmatory data.
But CMS cautions that the announcement should not be read as a preview of its upcoming national Medicare coverage decision on Aduhelm and similar treatments.